Detecting BRAF mutations in formalin-fixed melanoma: Experiences with twostate-of-the-art techniques

Case Reports in Oncology

Volumn 5, Issue 2, 2012, Pages 280-289

  Schoenewolf, Nicola L ^a   Dummer, Reinhard ^a   Mihic Probst, Daniela ^b   Moch, Holger ^b   Simcock, Mathew ^c   Ochsenbein, Adrian ^d   Gillessen, Silke ^e   Schraml, Peter ^b   Von Moos, Roger ^f  

^a Department of Dermatology ^*  (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c SAKK Coordinating Center   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f Kantonsspital Graubnden   (Switzerland)

Author keywords

BRAF mutations; Melanoma; Mutation detection methods; V600E

Indexed keywords

B RAF KINASE; BEVACIZUMAB; DNA; FORMALDEHYDE; TEMOZOLOMIDE;

ARTICLE; CLINICAL PROTOCOL; ELECTROPHORESIS; EXON; GENE MUTATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MELANOMA; PREDICTIVE VALUE; PRIORITY JOURNAL; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING; SURVIVAL; TISSUE FIXATION; WILD TYPE;

EID: 84866879524     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000339300     Document Type: Article

References (24)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA: Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
2. Kirschner M, Helmke B, Starz H, Benner A, Thome M, Deichmann M: Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases. Melanoma Res 2005;15:427-434.
3. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF: Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29:1239-1246.
4. Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, Tolbert D, Berwick M, Busam K, Begg CB, Mattingly D, Ollila DW, Tse CK, Hummer A, Lee-Taylor J, Conway K: Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma. Cancer Epidemiol Biomarkers Prev 2007;16:991-997.
5. Board RE, Ellison G, Orr MC, Kemsley KR, McWalter G, Blockley LY, Dearden SP, Morris C, Ranson M, Cantarini MV, Dive C, Hughes A: Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. Br J Cancer 2009;101:1724-1730.
6. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R, Marimuthu A, Nguyen H, Zhang KY, Artis DR, Schlessinger J, Su F, Higgins B, Iyer R, D'Andrea K, Koehler A, Stumm M, Lin PS, Lee RJ, Grippo J, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, Chapman PB, Flaherty KT, Xu X, Nathanson KL, Nolop K: Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010;467:596-599.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-2516.
8. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-819.
9. Lee JT, Li L, Brafford PA, van den Eijnden M, Halloran MB, Sproesser K, Haass NK, Smalley KS, Tsai J, Bollag G, Herlyn M: PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600Ee-positive melanomas. Pigment Cell Melanoma Res 2010;23:820-827.
10. Vultur A, Villanueva J, Herlyn M: Targeting BRAF in advanced melanoma: A first step toward manageable disease. Clin Cancer Res 2011;17:1658-1663.
11. Yang H, Higgins B, Kolinsky K, Packman K, Go Z, Iyer R, Kolis S, Zhao S, Lee R, Grippo JF, Schostack K, Simcox ME, Heimbrook D, Bollag G, Su F: RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res 2010;70:5518-5527.
12. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D, Halaban R: Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010;8:67.
13. von Moos R, Seifert B, Simcock M, Goldinger SM, Gillessen S, Ochsenbein A, Michielin O, Cathomas R, Schlappi M, Moch H, Schraml PH, Mjhic-Probst D, Mamot C, Schonewolf N, Dummer R: First-line temozolomide combined with bevacizumab in metastatic melanoma: A multicentre phase II trial (SAKK 50/07). Ann Oncol 2012;23:531-536.
14. Benlloch S, Paya A, Alenda C, Bessa X, Andreu M, Jover R, Castells A, Llor X, Aranda FI, Massuti B: Detection of BRAF V600E mutation in colorectal cancer: Comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 2006;8:540-543.
15. Domingo E, Laiho P, Ollikainen M, Pinto M, Wang L, French AJ, Westra J, Frebourg T, Espin E, Armengol M, Hamelin R, Yamamoto H, Hofstra RM, Seruca R, Lindblom A, Peltomaki P, Thibodeau SN, Aaltonen LA, Schwartz S Jr: BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004;41:664-668.
16. Ellison G, Donald E, McWalter G, Knight L, Fletcher L, Sherwood J, Cantarini M, Orr M, Speake G: A comparison of arms and DNA sequencing for mutation analysis in clinical biopsy samples. J Exp Clin Cancer Res 2010;29:132.
17. Kitago M, Koyanagi K, Nakamura T, Goto Y, Faries M, O'Day SJ, Morton DL, Ferrone S, Hoon DS: MRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads. Clin Chem 2009;55:757-764.
18. Kwak JY, Kim EK, Kim JK, Han JH, Hong SW, Park TS, Choi JR: Dual priming oligonucleotide-based multiplex PCR analysis for detection of BRAFV600E mutation in FNAB samples of thyroid nodules in BRAFV600E mutation-prevalent area. Head Neck 2010;32:490-498.
19. Miller CJ, Cheung M, Sharma A, Clarke L, Helm K, Mauger D, Robertson GP: Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms. J Invest Dermatol 2004;123:990-992.
20. Panka DJ, Sullivan RJ, Mier JW: An inexpensive, specific and highly sensitive protocol to detect the BrafV600E mutation in melanoma tumor biopsies and blood. Melanoma Res 2010;20:401-407.
21. Zatelli MC, Trasforini G, Leoni S, Frigato G, Buratto M, Tagliati F, Rossi R, Cavazzini L, Roti E, degli Uberti EC: BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 2009;161:467-473.
22. Perren A, Schmid S, Locher T, Saremaslani P, Bonvin C, Heitz PU, Komminoth P: BRAF and endocrine tumors: Mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr Relat Cancer 2004;11:855-860.
23. Hay R, MacRae E, Barber D, Khalil M, Demetrick DJ: BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products. Arch Pathol Lab Med 2007;131:1361-1367.
24. Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, Medina A, Letrero R, Herlyn M, Edwards RH: Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 2007;9:464-471.